RELMADA THERAPEUTICS, INC. Operating Leases, Rent Expense
RELMADA THERAPEUTICS, INC. (RLMD) reported Operating Leases, Rent Expense of $15.90 thousand for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseAndRentalExpense · last filed 2021-05-12
- RELMADA THERAPEUTICS, INC. operating leases, rent expense for the quarter ending 2021-03-31 was $15.90K, a 61.78% decline year-over-year.
- RELMADA THERAPEUTICS, INC. operating leases, rent expense for the quarter ending 2020-03-31 was $41.60K.
- RELMADA THERAPEUTICS, INC. operating leases, rent expense for the quarter ending 2016-03-31 was -$47.84K.
- RELMADA THERAPEUTICS, INC. operating leases, rent expense for fiscal 2019 was $114.80K, a 20.21% increase from fiscal 2018.
- RELMADA THERAPEUTICS, INC. operating leases, rent expense for fiscal 2018 was $95.50K, a 74.13% decline from fiscal 2017.
- RELMADA THERAPEUTICS, INC. operating leases, rent expense for fiscal 2017 was $369.20K.
| Period end | Operating Leases, Rent Expense 0 month | Operating Leases, Rent Expense 3 month | Operating Leases, Rent Expense 6 month | Operating Leases, Rent Expense 9 month | Operating Leases, Rent Expense 12 month |
|---|---|---|---|---|---|
| 2021-03-31 | $15.90K 10-Q · filed 2021-05-12 | ||||
| 2020-03-31 | $41.60K 10-Q · filed 2021-05-12 | ||||
| 2019-12-31 | $47.10K 10-KT · filed 2020-03-26 | ||||
| 2019-06-30 | $114.80K 10-KT · filed 2020-03-26 | ||||
| 2019-02-06 | $13.80K 10-Q · filed 2020-11-12 | ||||
| 2018-12-31 | $68.00K 10-KT · filed 2020-03-26 | ||||
| 2018-06-30 | $95.50K 10-KT · filed 2020-03-26 | ||||
| 2017-09-30 | $3.20K 10-K · filed 2018-09-28 | ||||
| 2017-06-30 | $369.20K 10-K · filed 2018-09-28 | ||||
| 2016-03-31 | -$47.84K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-09 | $164.92K 10-Q · filed 2016-05-09 | |||
| 2015-12-31 | $212.76K 10-Q · filed 2016-02-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |